Active ingredient description

It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AX Other antipsychotics
Discover more medicines within N05AX12

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₂₃H₂₇Cl₂N₃O₂
Molecular mass: 448.385 g/mol

External identifiers

CAS Substance: 129722-12-9
DrugBank Drug: DB01238
KEGG Drug: D01164
PubChem Compound: 60795
RxNorm Ingredient: 89013
SNOMED-CT Concept: 406784005
Aripiprazole (substance)
UNII Identifier: 82VFR53I78


Aripiprazole is an active ingredient of these brands:

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Ecuador (EC)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Italy (IT)

Japan (JP)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Nigeria (NG)

Singapore (SG)

Tunisia (TN)

United Kingdom (UK)

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.